Veteran entrepreneurs and cofounders of Actuate Therapeutics, Inc., Daniel Schmitt and Andrew Mazar, PhD, are taking no chances with their lead clinical candidate 9-ING-41, a promising new treatment for advanced and drug-resistant cancers and select inflammatory diseases.
CLP Spinout Rounds Third Base with New Treatment for Metastatic Cancers and Fibrosis
